Clinical Trials
7 trialsNCT04588922 2026-05-01
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT03850574 2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2 Recruiting
NCT04086264 2025-08-14
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie
Phase 1/2 Active not recruiting
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT02096042 2023-10-10
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown